Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 7/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27047926 | 0.98 | TDP1 (0.44) | CCNCCDK8TDP1BCHEBRD4 | |
| SCHEMBL12462274 | 0.90 | BCHE (0.40) | CCNCCDK8BCHESTK17BSTK17A | |
| SCHEMBL21065264 | 0.86 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL21065266 | 0.86 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL12462647 | 0.86 | TDP1 (0.52) | TDP1MEN1GAAKMT2A | |
| SCHEMBL14577308 | 0.85 | CCNC (0.37) | CCNCCDK8TDP1BCHEBRD4 | |
| SCHEMBL13684302 | 0.84 | ABL1 (0.38) | MEN1GAAKMT2A | |
| SCHEMBL19254473 | 0.84 | EPHX2 (0.38) | BRD4GAA | |
| SCHEMBL15119390 | 0.84 | ACHE (0.42) | BCHE | |
| SCHEMBL13997007 | 0.83 | EPHX1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11141368-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | L'OREAL (FR) | 2021-10-12 | — | — | US | disclosed |
| US-10813866-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | L'OREAL (FR) | 2020-10-27 | — | — | US | disclosed |
| EP-2521530-B1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | OREAL (FR) | 2019-06-26 | — | — | EP | disclosed |
| US-9561165-B2 | Cosmetic treatment processes and kit | L'OREAL (FR) | 2017-02-07 | — | — | US | disclosed |
| US-9561165-B2 | Cosmetic treatment processes and kit | L'OREAL (FR) | 2017-02-07 | — | — | US | disclosed |
| US-9089500-B2 | Cosmetic treatment processes and kit | L'OREAL (FR) | 2015-07-28 | — | — | US | disclosed |
| US-9089500-B2 | Cosmetic treatment processes and kit | L'OREAL (FR) | 2015-07-28 | — | — | US | disclosed |
| CN-104185469-A | Cosmetic treatment processes and kit | OREAL | 2014-12-03 | — | — | CN | disclosed |
| US-20140155352-A1 | COSMETIC TREATMENT PROCESSES AND KIT | L'OREAL (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155352-A1 | COSMETIC TREATMENT PROCESSES AND KIT | L'OREAL (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20130017162-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | L'OREAL (FR) | 2013-01-17 | — | — | US | disclosed |
| US-20130017162-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | L'OREAL (FR) | 2013-01-17 | — | — | US | disclosed |
| WO-2013004982-A2 | COSMETIC TREATMENT PROCESSES AND KIT | L'OREAL (FR) | 2013-01-10 | — | — | WO | disclosed |
| WO-2011083243-A1 | COSMETIC TREATMENT METHODS AND KIT | L'OREAL (FR) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011080494-A2 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | L'OREAL (FR) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155352-A1 | COSMETIC TREATMENT PROCESSES AND KIT | KIT, KRT18, MKI67 | CCNC 932/4885CDK8 1536/4885TDP1 1675/4885 |
| US-20130017162-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | KRT18, KIT, TYR | CCNC 570/4885CDK8 2358/4885TDP1 4164/4885 |
| US-10813866-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | KRT18, KIT, TYR | CCNC 570/4885CDK8 2358/4885TDP1 4164/4885 |
| US-11141368-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | KRT18, KIT, TYR | CCNC 570/4885CDK8 2358/4885TDP1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.